[A18-49] Emicizumab (haemophilia A) - Addendum to Commission A18-20
Last updated 20.09.2018
Commission awarded on 06.08.2018 by the Federal Joint Committee (G-BA).
Routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors
Conclusion of dossier assessment A18-20 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-20||Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V||Commission completed|